Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

92.70GBp
23 Nov 2017
Change (% chg)

-0.30 (-0.32%)
Prev Close
93.00
Open
93.30
Day's High
93.30
Day's Low
91.35
Volume
382,869
Avg. Vol
1,746,100
52-wk High
166.97
52-wk Low
86.50

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.43
Market Cap(Mil.): £631.40
Shares Outstanding(Mil.): 678.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

Nov 14 2017

UPDATE 1-Falls in Burberry, housebuilders pile pressure on FTSE

* Mid-cap Hikma's trading update disappoints (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

Nov 09 2017

Britain's FTSE under pressure as Burberry revamps its strategy

LONDON, Nov 9 A drop in luxury group Burberry weighed on the UK's top share index on Thursday, which was stuck below a five-month high as results were the main focus.

Nov 09 2017

UPDATE 1-UK Stocks-Factors to watch on Nov 9

Nov 9 Britain's FTSE 100 index futures are seen opening down 0.1 percent ahead of the cash market open.

Nov 09 2017

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler​

Oct 24 2017

BRIEF-Vectura updates on positive Flutiform K-haler regulatory progress

* ‍FLUTIFORM BREATH-ACTIVATED K-HALER MAKES POSITIVE EUROPEAN REGULATORY PROGRESS​

Oct 04 2017

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

Sep 06 2017

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

Sep 06 2017

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

Aug 17 2017

Vectura signs deal with Novartis for generic U.S. lung therapy

Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

Jun 28 2017

Earnings vs. Estimates